LncRNA LUCAT1 as a novel prognostic biomarker for patients with papillary thyroid cancer
In recent years, long non-coding RNAs have emerged as a novel class of regulators of cancer biological processes. While they are dysregulated in many cancer types, little is known about their expression and functional profiles. This study has been focused on the determination of the role of a specif...
Saved in:
Published in | Scientific reports Vol. 9; no. 1; pp. 14374 - 12 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
London
Nature Publishing Group UK
07.10.2019
Nature Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | In recent years, long non-coding RNAs have emerged as a novel class of regulators of cancer biological processes. While they are dysregulated in many cancer types, little is known about their expression and functional profiles. This study has been focused on the determination of the role of a specific lncRNA in papillary thyroid cancer. Quantitative reverse transcription PCR was performed to detect the expression levels of 84 lncRNAs in 61 papillary thyroid carcinoma tissues and their adjacent non-tumor tissues. The highest fold-change was obtained for lung cancer associated transcript 1
LUCAT1
, and thus, this study determines the expression and biological implication of lncRNA
LUCAT1
through different
in vitro
and
ex vivo
approaches in this tumor.
LUCAT1
was specifically located at the cell nucleus in tumoral regions of patient tissues. Furthermore,
LUCAT1
knockdown significantly reduced both cell proliferation and invasion
ex vivo
and induced cell-cycle arrest and apoptosis. These facts were corroborated by an enhanced expression of
P21
,
P57
,
P53
and
BAX
, and a reduced expression of
EZH2
and
HDAC1
. In addition, a significant decrease was observed on
DNMT1
and
NRF2
genes, helping to clarify the role of
LUCAT1
on PTC. Our study reveals the involvement of
LUCAT1
in PTC development, through acting in cell-cycle regulation, proliferation, epigenetic modifications through LUCAT1/ CDK1/ EZH2/ P57/ P21/ HDAC1/ DNMT1/ P53/ BAX axis and apoptosis, via extrinsic pathway activating caspases. These findings indicate that
LUCAT1
is maybe a potential therapeutic target and molecular biomarker for PTC. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 2045-2322 2045-2322 |
DOI: | 10.1038/s41598-019-50913-7 |